The 12-month price targets, analyzed by analysts, offer insights with an average target of $133.42, a high estimate of $155.00, and a low estimate of $110.00. A negative shift in sentiment is evident ...

Britain launched a life sciences sector plan on Wednesday to a mixed response from the pharmaceutical industry, which welcomed proposals to boost R&D but warned it would fail to keep firms competitive ...

The PD-1xVEGF dealmaking wave that has captivated Western pharma companies is now surging within China. | Sino Biopharm said it will pay up to $951 million to acquire LaNova Medicines, which has ...

BioNTech SE's turn toward oncology treatments has the potential to tap multi-billion-dollar markets in the future. Find out ...

The Victorian Government is investing $1.7 million into six new mRNA research projects aimed at accelerating breakthroughs.

According to Pfizer, "Hundreds of millions of doses of the Pfizer-BioNTech COVID-19 vaccine have been administered globally, and the benefit-risk profile of the vaccine remains positive for all ...

Shares of biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) fell 3.5% in the afternoon session after a cautious ...

In a report released today, Terence Flynn from Morgan Stanley maintained a Hold rating on Biogen, with a price target of $146.00. The company’s shares opened today at $132.99. E ...

Morgan Stanley analyst Terence Flynn maintained a Hold rating on Amgen today and set a price target of $330.00. The company’s shares opened today at $298.51. Elevate Your Invest ...

RFK Jr. cancels U.S. Preventive Services Task Force meeting; the Department of Health and Human Services backtracked on its claim that it would release ethics forms for new members of the Advisory ...

AbbVie licensed IGI's trispecific myeloma drug ISB 2001 in a deal worth up to $1.925 billion following strong early-phase ...

Pfizer (PFE) and BioNTech (BNTX) challenge Moderna's patent win in London court over mRNA COVID-19 vaccine technology. Read ...